Video

Dr. Monk on Emerging Therapies in Cervical Cancer

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Bradley J. Monk, MD, FACS, FACOG, US oncology medical director of Gynecologic Oncology Research and a professor at the University of Arizona College of Medicine, discusses emerging therapies in cervical cancer.

Early therapeutic intervention offers the best chance of survival in cervical cancer, explains Monk. Moreover, ​adding immunotherapy to chemoradiation for patients with unresectable locally advanced stage II and III disease could be a potentially promising approach.

Notably, the ​​phase 3 CALLA trial evaluating durvalumab (Imfinzi) plus chemoradiation and ​the phase 3 MK-3475-A18/KEYNOTE-A18/ENGOT-cx11 trial evaluating pembrolizumab (Keytruda) plus chemoradiation are ongoing global studies in this space.

The rationale for this research stems from the fact that chemoradiation can trigger an immune response. As such, the addition of a checkpoint inhibitor may result in a higher response rate compared with chemoradiation alone, Monk concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity